For Q1 FY2026 ended March 31, 2026, Vor Biopharma reported a net loss of $219.6 million, a significant increase from the prior year. Operating loss was $35.2 million, up 5.6% year-over-year. Diluted EPS was -$5.11, improving from -$5.31 in the prior year. Cash and cash equivalents stood at $169.9 million, with negative stockholders' equity of $150.4 million.
•Net loss widened to $219.6 million from $32.5 million in Q1 FY2025.
•Operating loss increased 5.6% to $35.2 million.
•Diluted EPS improved to -$5.11 from -$5.31.
•Cash of $169.9 million; no long-term debt reported.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company develops a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis Sjögren's disease and IgA nephrapathy.
It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. Incorporated in 2015, the company is headquartered in Boston, Massachusetts.
Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune diseases. Its lead product candidate is telitacicept, a novel fusion protein designed to treat conditions such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's disease, and IgA nephropathy. The company operates under a license agreement with RemeGen Co., Ltd., which grants Vor Biopharma rights to exploit, develop, and commercialize telitacicept and related products. As a clinical-stage company, Vor Biopharma is primarily engaged in research and development activities to advance its pipeline toward regulatory approval and eventual commercialization.
Where is Vor Biopharma Inc. listed and what currency does it trade in?
Vor Biopharma Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol VOR. The company trades in U.S. dollars (USD), which is the standard currency for stocks listed on U.S. exchanges. Being listed on NasdaqGS provides Vor Biopharma with access to a broad base of institutional and retail investors, as well as enhanced visibility within the global financial markets. Investors can buy and sell shares of Vor Biopharma through brokerage accounts that support trading on the Nasdaq exchange.
What sector and industry does Vor Biopharma Inc. belong to?
Vor Biopharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. This classification reflects the company's focus on developing biopharmaceutical products that leverage biological processes to treat diseases. As a biotechnology firm, Vor Biopharma engages in research, development, and potential commercialization of therapies that address unmet medical needs in autoimmune conditions. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant returns upon successful product launches. Vor Biopharma's pipeline, centered on telitacicept, positions it within the competitive landscape of autoimmune disease therapeutics.
Where is Vor Biopharma Inc. headquartered and what markets does it serve?
Vor Biopharma Inc. is headquartered in Boston, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its listing on the Nasdaq exchange and its focus on developing therapies for autoimmune diseases that affect patients globally. While its headquarters are in Boston, Vor Biopharma's operations are supported by its license agreement with RemeGen Co., Ltd., a Chinese biopharmaceutical company, which suggests potential collaboration or access to markets in Asia. However, as a clinical-stage company, Vor Biopharma's current market focus is on advancing its product candidate through clinical trials, with the aim of eventually obtaining regulatory approval to serve patients in the United States and possibly other regions.
What is Vor Biopharma Inc.'s business model and how does it generate revenue?
As a clinical-stage biopharmaceutical company, Vor Biopharma Inc. does not currently generate revenue from product sales. Its business model revolves around research and development of novel therapies, primarily telitacicept, for autoimmune diseases. The company's primary activities include conducting clinical trials, securing regulatory approvals, and preparing for commercialization. Vor Biopharma may generate revenue in the future through product sales, licensing agreements, or partnerships. Currently, it relies on funding from investors, grants, and its license agreement with RemeGen Co., Ltd., which provides rights to develop and commercialize telitacicept. The company's success depends on the successful development, regulatory approval, and market adoption of its pipeline candidates.